Clinical Application for Tissue Engineering Focused on Materials
Cardiovascular-related medical conditions remain a significant cause of death worldwide despite the advent of tissue engineering research more than half a century ago. Although autologous tissue is still the preferred treatment, donor tissue is limited, and there remains a need for tissue-engineered...
| Auteurs principaux: | , , , , , |
|---|---|
| Format: | Article |
| Langue: | English |
| Publié: |
MDPI AG
2022-06-01
|
| Collection: | Biomedicines |
| Sujets: | |
| Accès en ligne: | https://www.mdpi.com/2227-9059/10/6/1439 |
| _version_ | 1827662068771192832 |
|---|---|
| author | Takahiro Kitsuka Rikako Hama Anudari Ulziibayar Yuichi Matsuzaki John Kelly Toshiharu Shinoka |
| author_facet | Takahiro Kitsuka Rikako Hama Anudari Ulziibayar Yuichi Matsuzaki John Kelly Toshiharu Shinoka |
| author_sort | Takahiro Kitsuka |
| collection | DOAJ |
| description | Cardiovascular-related medical conditions remain a significant cause of death worldwide despite the advent of tissue engineering research more than half a century ago. Although autologous tissue is still the preferred treatment, donor tissue is limited, and there remains a need for tissue-engineered vascular grafts (TEVGs). The production of extensive vascular tissue (>1 cm<sup>3</sup>) in vitro meets the clinical needs of tissue grafts and biological research applications. The use of TEVGs in human patients remains limited due to issues related to thrombogenesis and stenosis. In addition to the advancement of simple manufacturing methods, the shift of attention to the combination of synthetic polymers and bio-derived materials and cell sources has enabled synergistic combinations of vascular tissue development. This review details the selection of biomaterials, cell sources and relevant clinical trials related to large diameter vascular grafts. Finally, we will discuss the remaining challenges in the tissue engineering field resulting from complex requirements by covering both basic and clinical research from the perspective of material design. |
| first_indexed | 2024-03-10T00:19:58Z |
| format | Article |
| id | doaj.art-8a7548dd2b714c0c901b16e162223a63 |
| institution | Directory Open Access Journal |
| issn | 2227-9059 |
| language | English |
| last_indexed | 2024-03-10T00:19:58Z |
| publishDate | 2022-06-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Biomedicines |
| spelling | doaj.art-8a7548dd2b714c0c901b16e162223a632023-11-23T15:44:52ZengMDPI AGBiomedicines2227-90592022-06-01106143910.3390/biomedicines10061439Clinical Application for Tissue Engineering Focused on MaterialsTakahiro Kitsuka0Rikako Hama1Anudari Ulziibayar2Yuichi Matsuzaki3John Kelly4Toshiharu Shinoka5Center for Regenerative Medicine, Nationwide Children’s Hospital, Columbus, OH 43205, USACenter for Regenerative Medicine, Nationwide Children’s Hospital, Columbus, OH 43205, USACenter for Regenerative Medicine, Nationwide Children’s Hospital, Columbus, OH 43205, USACenter for Regenerative Medicine, Nationwide Children’s Hospital, Columbus, OH 43205, USACenter for Regenerative Medicine, Nationwide Children’s Hospital, Columbus, OH 43205, USACenter for Regenerative Medicine, Nationwide Children’s Hospital, Columbus, OH 43205, USACardiovascular-related medical conditions remain a significant cause of death worldwide despite the advent of tissue engineering research more than half a century ago. Although autologous tissue is still the preferred treatment, donor tissue is limited, and there remains a need for tissue-engineered vascular grafts (TEVGs). The production of extensive vascular tissue (>1 cm<sup>3</sup>) in vitro meets the clinical needs of tissue grafts and biological research applications. The use of TEVGs in human patients remains limited due to issues related to thrombogenesis and stenosis. In addition to the advancement of simple manufacturing methods, the shift of attention to the combination of synthetic polymers and bio-derived materials and cell sources has enabled synergistic combinations of vascular tissue development. This review details the selection of biomaterials, cell sources and relevant clinical trials related to large diameter vascular grafts. Finally, we will discuss the remaining challenges in the tissue engineering field resulting from complex requirements by covering both basic and clinical research from the perspective of material design.https://www.mdpi.com/2227-9059/10/6/1439tissue engineeringtissue-engineered vascular grafts (TEVGs)biodegradable scaffoldssynthetic polymerssilk fibroindecellularized tissue |
| spellingShingle | Takahiro Kitsuka Rikako Hama Anudari Ulziibayar Yuichi Matsuzaki John Kelly Toshiharu Shinoka Clinical Application for Tissue Engineering Focused on Materials Biomedicines tissue engineering tissue-engineered vascular grafts (TEVGs) biodegradable scaffolds synthetic polymers silk fibroin decellularized tissue |
| title | Clinical Application for Tissue Engineering Focused on Materials |
| title_full | Clinical Application for Tissue Engineering Focused on Materials |
| title_fullStr | Clinical Application for Tissue Engineering Focused on Materials |
| title_full_unstemmed | Clinical Application for Tissue Engineering Focused on Materials |
| title_short | Clinical Application for Tissue Engineering Focused on Materials |
| title_sort | clinical application for tissue engineering focused on materials |
| topic | tissue engineering tissue-engineered vascular grafts (TEVGs) biodegradable scaffolds synthetic polymers silk fibroin decellularized tissue |
| url | https://www.mdpi.com/2227-9059/10/6/1439 |
| work_keys_str_mv | AT takahirokitsuka clinicalapplicationfortissueengineeringfocusedonmaterials AT rikakohama clinicalapplicationfortissueengineeringfocusedonmaterials AT anudariulziibayar clinicalapplicationfortissueengineeringfocusedonmaterials AT yuichimatsuzaki clinicalapplicationfortissueengineeringfocusedonmaterials AT johnkelly clinicalapplicationfortissueengineeringfocusedonmaterials AT toshiharushinoka clinicalapplicationfortissueengineeringfocusedonmaterials |